Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials-Reference-Cited by-同舟云学术

Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials

Published:2010-09 Issue:9 Volume:21 Page:1743-1750
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bujko K.,Glynne-Jones R.,Bujko M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/9/1743/341084/mdq054.pdf

Reference55 articles.

1. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and evaluation of late secondary effects;Frykholm;Dis Colon Rectum,1993

2. Preoperative versus postoperative chemoradiotherapy for rectal cancer;Sauer;N Engl J Med,2004

3. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials;Sakamoto;Jap J Clin Oncol,1999

4. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer;Sakamoto;Br J Cancer,2007

5. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence;Kusters;Ann Surg,2009

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinical relevance of adjuvant chemotherapy in locally advanced rectal cancer patients achieving near pathological complete response following neoadjuvant chemoradiotherapy: Insights from ypT stage;European Journal of Surgical Oncology;2024-04

2. Are we in the era of total neoadjuvant treatment in rectal cancer?;Onkologie;2023-03-01

3. Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review;Current Oncology Reports;2023-02-13

4. Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses;Frontiers in Oncology;2023-01-30

5. Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis;Cancer Genetics;2022-11